1760 — Panion & BF Biotech Balance Sheet
0.000.00%
- TWD5.80bn
- TWD5.95bn
- TWD2.03bn
- 82
- 25
- 33
- 44
Annual balance sheet for Panion & BF Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 406 | 349 | 464 | 535 | 558 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 450 | 363 | 361 | 359 | 401 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,454 | 1,275 | 1,399 | 1,477 | 1,510 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,476 | 1,524 | 1,562 | 1,635 | 1,614 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 3,074 | 2,953 | 3,094 | 3,235 | 3,208 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 946 | 740 | 922 | 1,051 | 1,027 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,834 | 1,020 | 1,086 | 1,324 | 1,286 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1,240 | 1,933 | 2,007 | 1,911 | 1,922 |
Total Liabilities & Shareholders' Equity | 3,074 | 2,953 | 3,094 | 3,235 | 3,208 |
Total Common Shares Outstanding |